Clinuvel Pharmaceuticals Limited (OTCMKTS:CLVLY – Get Free Report) was the target of a large growth in short interest during the month of May. As of May 15th, there was short interest totaling 1,399 shares, a growth of 329.1% from the April 30th total of 326 shares. Based on an average daily volume of 1,818 shares, the short-interest ratio is currently 0.8 days.
Clinuvel Pharmaceuticals Stock Performance
OTCMKTS:CLVLY opened at $6.56 on Friday. Clinuvel Pharmaceuticals has a 12-month low of $5.98 and a 12-month high of $9.00. The stock’s fifty day simple moving average is $6.69 and its 200-day simple moving average is $7.46.
Clinuvel Pharmaceuticals Company Profile
Clinuvel Pharmaceuticals Limited is an Australian biopharmaceutical company headquartered in Melbourne, specializing in the development and commercialisation of photoprotective and phototherapeutic solutions. The company’s research centers on harnessing the skin’s natural photoprotective pathways by modulating the melanocortin system, with a view to addressing a range of skin disorders and conditions that are exacerbated by ultraviolet light exposure.
The company’s flagship product, Scenesse (afamelanotide), is the first systemic photoprotective drug approved by both the European Medicines Agency and the U.S.
Read More
- Five stocks we like better than Clinuvel Pharmaceuticals
- 3 Stocks Rallying on Micron’s Price Boost: Substance or Hype?
- Snowflake and the Snowballing Impact of its AI Flywheel
- AI’s Biggest Bottleneck Could Make These 2 Stocks Soar
- These 3 Beaten-Down Stocks Just Saw $25 Million in Insider Buying
Receive News & Ratings for Clinuvel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinuvel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
